Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
Zobair M. Younossi, James M. Paik, Reem Q. Al Shabeeb, et al.
Hepatology (2022) Vol. 76, Iss. 5, pp. 1423-1437
Closed Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 245
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
Zobair M. Younossi, James M. Paik, Maria Stepanova, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 5, pp. 694-701
Closed Access | Times Cited: 142
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 92
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis
Ansel Shao Pin Tang, Cheng Han Ng, Poh Hui Phang, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 7, pp. 1750-1760.e12
Closed Access | Times Cited: 76
Dietary Quality and Relationships with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among United States Adults, Results from NHANES 2017–2018
Ting Tian, Jingxian Zhang, Wei Xie, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4505-4505
Open Access | Times Cited: 73
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 58
Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
Rui Song, Li Zhao, Yingzhi Zhang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 1051-1060
Closed Access | Times Cited: 50
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Pegah Golabi, James M. Paik, Ameeta Ravi Kumar, et al.
Metabolism (2023) Vol. 146, pp. 155642-155642
Closed Access | Times Cited: 47
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
David Martí‐Aguado, José Luís Calleja, Eduardo Vilar‐Gómez, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 6, pp. 930-940
Closed Access | Times Cited: 35
Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
Laurens A. van Kleef, Sven Francque, Jhon Edison Prieto Ortíz, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 357-367.e9
Open Access | Times Cited: 20
Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease
Keito Suzuki, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Hepatology Research (2024) Vol. 54, Iss. 6, pp. 600-605
Closed Access | Times Cited: 17
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
Pegah Golabi, Soroor Owrangi, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 17
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Comparison of mortality outcomes in individuals with MASLD and/or MAFLD
Qianwen Zhao, Yunlei Deng
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. e62-e64
Open Access | Times Cited: 38
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1097-1097
Open Access | Times Cited: 26
Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
Mengqi Li, Wen Xie
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. e53-e54
Closed Access | Times Cited: 26
Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis
Yudi Liao, Liya Wang, Fang Liu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 24
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 16
Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes
Yi‐Ting Chen, Tzu-I Chen, Tsai-Hsuan Yang, et al.
The American Journal of Gastroenterology (2024)
Open Access | Times Cited: 14
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study
Sung Won Chung, Hye‐Sung Moon, Hyun‐Jae Shin, et al.
Hepatology (2024) Vol. 80, Iss. 3, pp. 633-648
Closed Access | Times Cited: 12
Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 10
Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies
Grazia Pennisi, G. Infantino, Ciro Celsa, et al.
Liver International (2024) Vol. 44, Iss. 11, pp. 2939-2949
Open Access | Times Cited: 9
miR‐18a‐5p/PXR/SREBP2 Was Involved in MAFLD Associated With Methyl Tert‐Butyl Ether Among Petrol Station Workers
H. Wang, Mingxiao Guo, Fengtao Cui, et al.
Liver International (2025) Vol. 45, Iss. 2
Closed Access | Times Cited: 1
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
Mark Muthiah, Cheng Han Ng, Kai En Chan, et al.
Annals of Hepatology (2022) Vol. 28, Iss. 1, pp. 100762-100762
Open Access | Times Cited: 36
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
Karl Vaz, Daniel Clayton‐Chubb, Ammar Majeed, et al.
Hepatology International (2023) Vol. 17, Iss. 5, pp. 1082-1097
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top